Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106Robert W Chen, Hongli Li, Steven H Bernstein, et al.
Blood|August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinibXin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
Blood|November 19, 2021
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapyMelissa M Berrien-Elliott, Michelle Becker-Hapak, Amanda F Cashen, et al.
Blood|April 15, 2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trialTait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
British Journal of Haematology|September 28, 2021
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantationPeter A Riedell, Mehdi Hamadani, Kwang W Ahn, et al.
Nature Communications|February 2, 2018
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potentialTerrence N Wong, Christopher A Miller, Matthew R M Jotte, et al.
Blood Advances|July 26, 2023
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303David A Russler-Germain, Kilannin Krysiak, Cody Ramirez, et al.
Blood|February 22, 2018
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantationRizwan Romee, Sarah Cooley, Melissa M Berrien-Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin LymphomaJennifer A Foltz, Brian T Hess, Veronika Bachanova, et al.
Blood|December 6, 2021
Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplantJeffrey J Bednarski, Clare Zimmerman, Melissa M Berrien-Elliott, et al.
Pageof 10